Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

2.1 Fedratinib (Inrebic, Celgene) has a marketing authorisation for 'the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naive or have been treated with ruxolitinib'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of fedratinib is £6,120 for a 120‑capsule pack of 100 mg capsules (excluding VAT; BNF online accessed September 2021). The company has a commercial arrangement. This makes fedratinib available to the NHS with a discount. The size of the discount is commercial in confidence. It's the company's responsibility to let relevant NHS organisations know details of the discount.